We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers

By LabMedica International staff writers
Posted on 08 Jan 2025

Immune checkpoint inhibitors, a form of immunotherapy, are a potent tool in the fight against cancer. More...

These inhibitors target the immune system, not the cancer directly. They work by releasing the brakes on immune cells, enhancing their ability to attack cancer. However, these drugs are costly and can cause severe side effects, as well as ineffective for most patients. Thus, selecting the right patients is crucial — matching the drugs to those most likely to benefit. While there are existing methods to predict whether tumors will respond to these drugs, they typically require advanced genomic testing, which is not widely accessible globally. Now, a new tool may soon be available to doctors worldwide that could more accurately predict whether individual cancer patients will benefit from immune checkpoint inhibitors, using only routine blood tests and clinical data.

Researchers from Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA) and the Tisch Cancer Institute at Mount Sinai (Mount Sinai, New York, NY, USA) have developed an AI-based model called SCORPIO. The model is not only more affordable and accessible but also significantly more effective at predicting patient outcomes than the two biomarkers currently approved by the U.S. Food and Drug Administration (FDA), according to a study published in Nature Medicine. The two FDA-approved biomarkers for predicting response to checkpoint inhibitors are tumor mutational burden (which measures mutations in a tumor) and PD-L1 immunohistochemistry (which evaluates the expression of the PD-L1 protein in tumor samples). Both methods require tumor samples. Genomic testing for mutations is costly and not available everywhere, and there is considerable variability in evaluating PD-L1 expression.

SCORPIO, in contrast, uses readily accessible clinical data, including routine blood tests, such as the complete blood count and the comprehensive metabolic profile, which are performed in clinics worldwide. The researchers discovered that SCORPIO outperforms the current clinical tests. This simple, affordable approach could improve access to care, reduce costs, and ensure that patients receive the right treatments. Initially developed by the MSK team with data from MSK patients, SCORPIO was further enhanced in collaboration with Mount Sinai researchers using ensemble machine learning — an AI technique that combines multiple tools to detect patterns in clinical data from blood tests and treatment outcomes. The model was trained using retrospective data from over 2,000 MSK patients treated with checkpoint inhibitors, spanning 17 types of cancer. The model was then tested on data from an additional 2,100 MSK patients to confirm its high accuracy in predicting outcomes.

Next, the team applied the model to nearly 4,500 patients treated with checkpoint inhibitors across 10 different phase 3 clinical trials worldwide. Additional validation was done with data from almost 1,200 patients treated at Mount Sinai. In total, the study encompasses nearly 10,000 patients from 21 different cancer types, making it the largest cancer immunotherapy dataset to date. This extensive testing and validation were carried out not only to develop a predictive model but to create one that is widely applicable to patients and physicians in various locations. The team plans to collaborate with hospitals and cancer centers globally to test the model using more data from diverse clinical settings while optimizing it based on feedback. They are also working on developing a user-friendly interface for clinicians, making it accessible wherever they may be located.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
New
Glucose Tolerance Test
NERL Trutol
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: New biomarkers could someday make it easy to spot Parkinson’s disease in a patient’s blood sample (Photo courtesy of Shutterstock)

Unique Blood-Based Genetic Signature Can Diagnose Parkinson’s Disease

Parkinson's disease is primarily recognized for its impact on the central nervous system. Recent scientific progress has shifted focus to understanding the involvement of the immune system in the onset... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: The innovative doublet configuration and annular illumination overcome traditional metalens limitations (Photo courtesy of Tao Li and Jiacheng Sun/Nanjing University)

High-Resolution Metalens Doublet Microscope to Enhance Diagnostic Capabilities

Metalenses mark a groundbreaking leap in optical technology. Unlike traditional microscope objectives that rely on curved glass surfaces, metalenses utilize nanoscale structures to manipulate light at... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.